국소 마취제 시장 보고서 : 약물 유형, 투여 방법, 유통 채널 및 지역별(2024-2032년)

The global local anesthesia drugs market size reached US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032.

Local anesthesia drugs are chemical compounds producing anesthesia by inhibiting the excitation of nerve endings or blocking conduction in peripheral nerves. They are generally available as topical creams or administered via injections or sprays during minor surgeries, biopsies, dental care, labor and delivery, and obstetrical procedures. They help treat painful conditions, such as mouth ulcers and sore throat, and relieve itching caused by cuts, minor burns, sunburns, scratches, insect bites, and poison ivy. They also assist in rapid and effective pain relief during gastritis, esophagitis, hiatus hernia, and heartburn of peptic ulcer.

Local Anesthesia Drugs Market Trends:

The rising prevalence of cardiovascular, respiratory, and other chronic diseases that need several procedures, such as cochlear implantation, laparoscopic colectomy, laparoscopic hysterectomy, secondary hip replacement, and knee replacement, represents one of the key factors bolstering the market growth. Furthermore, the growing geriatric population undergoing surgical interventions that require post-operative pain relief is catalyzing the demand for local anesthesia drugs across the globe. Moreover, the increasing number of dental surgeries, in confluence with the introduction of novel and effective medicines like articaine, levobupivacaine and ropivacaine, is propelling the market growth. Apart from this, due to the increasing consciousness about physical appearance among individuals, there is a rise in the demand for minimally invasive (MI) cosmetic surgical procedures, such as botulinum toxin and facial filler injections, which is contributing to the market growth. In addition to this, expanding medical tourism activities, along with developments in the healthcare infrastructure, are creating a positive market outlook. Besides this, technological advancements, including computer-based local anesthetic delivery and vibrotactile devices, are anticipated to provide a positive thrust to the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global local anesthesia drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug type, mode of administration and distribution channel.

Breakup by Drug Type:

Lidocaine

Bupivacaine

Benzocaine

Ropivacaine

Prilocaine

Chloroprocaine

Others

Breakup by Mode of Administration:

Injectables

Surface Anesthetic

Breakup by Distribution Channel:

Hospital Pharmacy

Pharmacy Stores

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aspen Pharmacare Holdings Limited, B. Braun Melsungen AG, Baxter International Inc., Endo International plc, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Pacira Biosciences Inc., Pfizer Inc., Pierrel S.p.A. and Septodont.

Key Questions Answered in This Report

• 1. What was the size of the global local anesthesia drugs market in 2023?
• 2. What is the expected growth rate of the global local anesthesia drugs market during 2024-2032?
• 3. What are the key factors driving the global local anesthesia drugs market?
• 4. What has been the impact of COVID-19 on the global local anesthesia drugs market?
• 5. What is the breakup of the global local anesthesia drugs market based on the drug type?
• 6. What is the breakup of the global local anesthesia drugs market based on the mode of administration?
• 7. What is the breakup of the global local anesthesia drugs market based on the distribution channel?
• 8. What are the key regions in the global local anesthesia drugs market?
• 9. Who are the key players/companies in the global local anesthesia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Local Anesthesia Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Lidocaine
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Bupivacaine
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Benzocaine
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Ropivacaine
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Prilocaine
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Chloroprocaine
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Mode of Administration

• 7.1 Injectables
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Surface Anesthetic
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacy
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Pharmacy Stores
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Aspen Pharmacare Holdings Limited
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Drug Type Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 B. Braun Melsungen AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Drug Type Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Baxter International Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Drug Type Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Endo International plc
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Drug Type Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Fresenius SE & Co. KGaA
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Drug Type Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Hikma Pharmaceuticals plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Drug Type Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Pacira Biosciences Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Drug Type Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Drug Type Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Pierrel S.p.A.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Drug Type Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Septodont
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Drug Type Portfolio